Cancer types · Blood cancers
Other Haematological Malignancies
This group includes myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) such as polycythaemia vera, essential thrombocythaemia and myelofibrosis, and rarer conditions such as systemic mastocytosis and histiocytic neoplasms.
Molecular results increasingly inform diagnosis and risk assessment in these conditions.
Clinical and molecular questions that often arise
- Which condition has been diagnosed, and on what criteria?
- Which driver mutations were found (for example JAK2, CALR or MPL in MPN)?
- How do molecular findings change the risk assessment in MDS?
- Is there a question about progression to acute leukaemia?
Information that may be part of an individual assessment
- Blood counts and blood film.
- Bone marrow examination.
- Cytogenetics and myeloid molecular panels.
Which investigations are appropriate is decided by the treating team for each person.
Molecular profiling and biomarker interpretation
Depending on the setting, molecular and biomarker questions in other haematological malignancies may involve:
- JAK2 V617F, CALR and MPL driver mutations in MPN
- SF3B1, TP53, ASXL1 and RUNX1 in MDS risk models
- KIT D816V in systemic mastocytosis
- BRAF V600E and MAP2K1 in histiocytic neoplasms
Biomarkers, panels and available tests vary by subtype, disease setting, assay and guideline version. A detected alteration is not automatically actionable.
How KPCIRC pathways may apply
POAS
POAS may help interpret a myeloid panel, distinguishing driver mutations and risk-relevant findings from variants of uncertain significance.
Molecular Tumour Board
Haemato-oncology or MTB discussion may help where results are complex or the clinical course changes.
Second opinion and progression review
A second opinion may help clarify the diagnosis or risk category. Progression review can organise changes in counts and molecular findings.
Hereditary risk and screening
Some myeloid conditions are linked to inherited predisposition. A genetics discussion may be relevant when results or family history suggest it.
How to access the relevant pathway
Patients and families
- Talk to your treating oncologist about whether an additional review may help.
- Request a consultation and tell us which question you want answered.
- Share records only when asked, through the secure route.
Referring doctors
- Define the clinical question and the pathway: POAS, MTB, second opinion or progression review.
- Start a case enquiry without patient identifiers.
- Scope, fees and timing are confirmed before any review proceeds.
Questions and limitations
Are these conditions leukaemia?
They are blood cancers related to leukaemia. Some can progress to acute leukaemia, which is why monitoring matters.
Why do mutations change the risk score?
Modern risk models incorporate molecular results because they add information beyond blood counts and cytogenetics.
Does this page apply to my situation?
This page is educational. It explains common questions but cannot account for individual circumstances. Your treating clinician is best placed to interpret your reports and plan your care.
Educational content reviewed against the KPCIRC service scope. It is not a diagnosis, a treatment recommendation or a statement that a specialist or service is available for this cancer type.